238 related articles for article (PubMed ID: 9005678)
21. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
22. Detection of minimal residual disease in leukemias: a critical approach.
Baruchel A; Schaison G
Nouv Rev Fr Hematol (1978); 1990; 32(1):21-4. PubMed ID: 2190175
[TBL] [Abstract][Full Text] [Related]
23. [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
Hokland P; Nyvold CG; Stentoft J; Ommen HB; Ebbesen LH; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
Ugeskr Laeger; 2009 Jan; 171(4):229-31. PubMed ID: 19174037
[TBL] [Abstract][Full Text] [Related]
24. Establishing the method of chimerism monitoring after allogeneic stem cell transplantation using multiplex polymerase chain reaction amplification of short tandem repeat markers and Amelogenin.
Sufliarska S; Minarik G; Horakova J; Bodova I; Bojtarova E; Czako B; Mistrik M; Drgona L; Demitrovicova M; Lakota J; Krivosikova M; Kovacs L
Neoplasma; 2007; 54(5):424-30. PubMed ID: 17688372
[TBL] [Abstract][Full Text] [Related]
25. Monitoring minimal residual disease in AML: the right time for real time.
Jaeger U; Kainz B
Ann Hematol; 2003 Mar; 82(3):139-47. PubMed ID: 12634945
[TBL] [Abstract][Full Text] [Related]
26. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.
Breccia M; Diverio D; Noguera NI; Visani G; Santoro A; Locatelli F; Damiani D; Marmont F; Vignetti M; Petti MC; Lo Coco F
Haematologica; 2004 Jan; 89(1):29-33. PubMed ID: 14754603
[TBL] [Abstract][Full Text] [Related]
27. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Schoch C; Haferlach T; Schnittger S
Crit Rev Oncol Hematol; 2005 Nov; 56(2):283-309. PubMed ID: 16213150
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of genetic markers in chronic myelogenous leukemia patients after bone marrow transplantation.
Zámecníková A; Kri an P; Mistrík M
Neoplasma; 2000; 47(5):299-302. PubMed ID: 11130247
[TBL] [Abstract][Full Text] [Related]
29. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
[TBL] [Abstract][Full Text] [Related]
30. Clinical applications of molecular monitoring in leukemia.
Maslak P
Curr Hematol Rep; 2003 Jan; 2(1):43-8. PubMed ID: 12901153
[TBL] [Abstract][Full Text] [Related]
31. Molecular detection of low-level disease in patients with cancer.
Burchill SA; Selby PJ
J Pathol; 2000 Jan; 190(1):6-14. PubMed ID: 10640986
[TBL] [Abstract][Full Text] [Related]
32. Detection of minimal residual disease in leukemia using polymerase chain reaction and restriction analysis.
Wu N; Lu S; Zhu P; Liu L; Peng Y
Chin Med J (Engl); 1997 Jan; 110(1):73-7. PubMed ID: 9594329
[TBL] [Abstract][Full Text] [Related]
33. [Clinical importance of semi-quantitative monitoring of lymphomas using the comparative polymerase chain reaction].
Slavícková A; Ivánek R; Cerný J; Sálková J; Trnĕný M
Cas Lek Cesk; 2002 Nov; 141(23):735-8. PubMed ID: 12650030
[TBL] [Abstract][Full Text] [Related]
34. [Residual disease: the hematologist's point of view].
Quesnel B; Preudhomme C
Bull Cancer; 2001 Jun; 88(6):571-5. PubMed ID: 11459703
[TBL] [Abstract][Full Text] [Related]
35. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G;
Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
[TBL] [Abstract][Full Text] [Related]
36. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
37. Detection and significance of minimal residual disease in patients with leukaemia and lymphoma.
Goldman JM; Hughes T
Bone Marrow Transplant; 1991; 7 Suppl 1():66-9. PubMed ID: 2043891
[No Abstract] [Full Text] [Related]
38. [Molecular markers in hematology and oncology].
Schmidt A
Praxis (Bern 1994); 2010 Sep; 99(19):1143-52. PubMed ID: 20859878
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in diagnosis and classification of leukemias and lymphomas.
Naeim F; Gatti RA; Yunis JJ
Dis Markers; 1990; 8(5):231-64. PubMed ID: 1707768
[No Abstract] [Full Text] [Related]
40. [Significance of tumor markers in the treatment of cancer: hematologic malignancy].
Sampi K
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3041-5. PubMed ID: 3674891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
